|
|
| Research article summary (published 7 Sep 2009): |
Do immunotherapy and beta cell replacement play a synergistic role in the treatment of type 1 diabetes?
Full Abstract
Type 1 diabetes (T1D) is the result of the autoimmune response against pancreatic insulin-producing ss-cells. Its ultimate consequence is beta-cell insufficiency-mediated dysregulation of blood glucose control. In terms of T1D treatment, immunotherapy addresses the cause of T1D, mainly through re-setting the balance between autoimmunity and regulatory mechanisms. Regulatory T cells play an important role in this immune intervention. An alternative T1D treatment is beta-cell replacement, which can reverse the consequence of the disease by replacing destroyed beta-cells in the diabetic pancreas. The applicable insulin-producing cells can be directly obtained from islet transplantation or generated from other cell sources such as autologous adult stem cells, embryonic stem cells, and induced pluripotent stem cells. In this review, we summarize the recent research progress and analyze the possible advantages and disadvantages of these two therapeutic options especially focusing on the potential synergistic effect on T1D treatment. Exploring the optimal combination of immunotherapy and beta-cell replacement will pave the way to the most effective cure for this devastating disease.
Author information
Author/s: Li, Dong-Sheng (DS); Warnock, Garth L (GL); Tu, Han-Jun (HJ); Ao, Ziliang (Z); He, Zehua (Z); Lu, Hong (H); Dai, Long-Jun (LJ);
Affiliation: Tai-He Hospital, Yunyang Medical College, Shiyan, Hubei, China.
Journal and publication information
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
Journal: Life sciences (Life Sci), published in Netherlands. (Language: eng)
Reference: 2009-Oct; vol 85 (issue 15-16) : pp 549-56
Dates: Created 2009/09/28; Completed 2009/10/08;
PMID: 19747492, status: MEDLINE (last retrieval date: 10/8/2009, IMS Date: )
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
Related articles
These are the highest related articles currently in the database:
- [Regenerative cell therapy of the type I diabetes mellitus and its complications]
30 Dec 2007 - Beta-cell replacement for insulin-dependent diabetes mellitus.
9 Oct 2007 - Feasibility, safety, and efficacy of percutaneous transhepatic injection of beta-cell grafts.
29 Nov 2005 - CD3-specific antibodies: a portal to the treatment of autoimmunity.
18 Jul 2007 - Islet neogenesis: a potential therapeutic tool in type 1 diabetes.
25 Sep 2005 - The type and frequency of immunoregulatory CD4+ T-cells govern the efficacy of antigen-specific immunotherapy in nonobese diabetic mice.
20 Feb 2007 - Beta-cell replacement in immunosuppressed recipients: old and new clinical indications.
7 Oct 2007 - Immunotherapy for the prevention and treatment of type 1 diabetes.
30 Aug 2005 - Achieving antigen-specific tolerance in diabetes: regulating specifically.
30 Aug 2005 - [Immuno- and regeneration therapy of recently diagnosed diabetes mellitus type I]
27 Feb 1985
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a large map of 100+ related articles.